A detailed history of Wellington Management Group LLP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Wellington Management Group LLP holds 235,987 shares of VRDN stock, worth $4.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
235,987
Previous 284,044 16.92%
Holding current value
$4.7 Million
Previous $3.7 Million 45.28%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.16 - $23.33 $584,373 - $1.12 Million
-48,057 Reduced 16.92%
235,987 $5.37 Million
Q2 2024

Aug 13, 2024

BUY
$11.6 - $17.26 $501,294 - $745,890
43,215 Added 17.94%
284,044 $3.7 Million
Q1 2024

May 15, 2024

BUY
$17.09 - $23.82 $4.12 Million - $5.74 Million
240,829 New
240,829 $4.22 Million
Q4 2023

Feb 12, 2024

BUY
$11.12 - $22.5 $2.14 Million - $4.32 Million
192,097 New
192,097 $4.18 Million
Q3 2023

Nov 14, 2023

BUY
$15.16 - $24.7 $657,170 - $1.07 Million
43,349 Added 25.16%
215,648 $3.31 Million
Q2 2023

Aug 14, 2023

BUY
$22.57 - $29.67 $1.08 Million - $1.42 Million
47,903 Added 38.51%
172,299 $4.1 Million
Q1 2023

May 12, 2023

BUY
$25.04 - $37.6 $97,480 - $146,376
3,893 Added 3.23%
124,396 $3.16 Million
Q4 2022

Feb 13, 2023

BUY
$18.78 - $29.74 $2.26 Million - $3.58 Million
120,503 New
120,503 $3.52 Million
Q3 2021

Nov 15, 2021

SELL
$10.69 - $18.2 $6.18 Million - $10.5 Million
-578,560 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$15.5 - $24.93 $8.97 Million - $14.4 Million
578,560 New
578,560 $9.67 Million

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $795M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.